X-rays expose blueprint for possible sleeping sickness drug

November 29, 2012

Using the world's most powerful X-ray laser, scientists have exposed a possible Achilles' heel of the sleeping sickness parasite that threatens more than 60 million people in sub-Saharan Africa. The sophisticated analysis revealed the blueprint for a molecular plug that can selectively block a vital enzyme of the parasite Trypanosoma brucei. Plugging such a tailor-made molecule into the right place of the enzyme would render it inactive, thereby killing the parasite. The team led by DESY scientist Prof. Henry Chapman from the Center of Free-Electron Laser Science (CFEL), Prof. Christian Betzel from the University of Hamburg and Dr. Lars Redecke from the joint Junior Research Group "Structural Infection Biology using new Radiation Sources (SIAS)" of the Universities of Hamburg and Lübeck report their findings in the journal Science. "This is the first new biological structure solved with a free-electron laser," said Chapman.

The researchers had investigated tiny crystals of the parasite's enzyme cathepsin B with intense X-rays from the free-electron laser Linac Coherent Light Source (LCLS) at the US National Accelerator Laboratory SLAC in California. "The enzyme had emerged as a promising drug target in earlier trials", said Redecke, one of the first authors of the scientific paper. "The knockdown of this essential enzyme in the parasite did cure the infection in mice."

But the same enzyme is also part of the human - and in fact of all mammalian - biochemistry, and blocking it has severe consequences. With their analysis the scientists could now pinpoint distinctive structural differences between the human and the parasite's form of the enzyme. "This should in principle allow for designing a molecule that selectively blocks the parasite's enzyme while leaving the patient's intact", explained the other first author of the paper, Karol Nass, PhD student at the Hamburg School for Structure and Dynamics in Infection (SDI), funded by the Excellence Initiative of the German Federal State of Hamburg (LEXI), The researchers stress that while the finding raises hopes, a possible new drug is still a long way to go.

Sleeping sickness, or human African trypanosomiasis (HAT), is transmitted by the bite of the tsetse fly. The Trypanosoma parasites invade the central nervous system, and without treatment the infection is usually fatal. The disease occurs in 36 sub-Saharan countries and affects mostly poor populations living in remote rural areas. Thanks to intensified control measures the number of reported cases fell steeply in recent years, but there are still millions at risk. Current treatments of HAT rely on anti-parasitic drugs developed without knowledge of the biochemical pathways. They are not always as effective and as safe as desired, and the parasites are increasingly becoming resistant to these drugs. New drugs that selectively kill the parasite without affecting the patient's own organism would be of great use.

With cathepsin B the scientists applied a novel approach by investigating tiny crystals of the enzyme that were grown in insect cells in vivo. This way the enzyme was frozen in its natural configuration that includes a native inhibitor. Because cathepsin B works as a sort of molecular scissors cutting away at other proteins, it is produced by the cell in an inhibited form and only activated when needed. In the inhibited form a small peptide molecule is blocking the cutting edge of the molecular scissors. "With the peptide still in place we could peer below a previously impenetrable part of the cathepsin B structure ", explained Betzel. There, the analysis revealed significant differences between the peptide binding sites at the parasite's and the human form of cathepsin B. "This way, nature provided us with a blueprint of what an artificial inhibitor for the parasite's enzyme could look like." The next step would be to synthesise such a tailor-made plug and test it in the lab.

The molecular structure of the enzyme was solved to the atomic level by shooting bright X-ray flashes at the tiny cathepsin B crystals, which were only about a micron (a thousandth of a millimetre) in diameter and about ten microns long on average. Crystals scatter X-rays in a characteristic way that depends on their inner structure. From the resulting diffraction pattern the structure of the crystals can be calculated, in this case revealing the structure of the enzyme. Today, crystallography is a standard technique to analyse biomolecules. Usually, scientists use modified bacteria to produce biomolecules in large amounts and try to crystallise them into the largest possible sizes of high-quality crystals afterwards. The in vivo crystallisation pioneered at the labs of Betzel and Prof. Michael Duszenko at the University of Tübingen, who is also a member of the research team, employs living cells to produce crystals. In contrast to standard crystallisation experiments, only in vivo crystallisation yielded suitable crystals of cathepsin B in a natively inhibited form.

But the in vivo crystals are still so small that only X-ray lasers like LCLS are bright enough to produce sufficiently detailed diffraction images. The LCLS belongs to a novel class of scientific light sources called free-electron lasers that are based on powerful particle accelerators. In these machines, electrons are accelerated to high speeds, or energies, and are then forced on a tight slalom course. In every bend each electron emits a tiny flash, and all the flashes add up to an incredibly strong X-ray pulse with laser properties, that allows to resolve structures like the natively inhibited cathepsin B molecule.

To solve the cathepsin B structure the researchers had to record hundreds of thousands of diffraction images that were painstakingly stitched together afterwards. As each crystal is destroyed when hit by the powerful X-ray flash, the team fed a stream of crystals in a watery solution through a thin nozzle into the laser path. The X-ray laser fired away at 120 shots per second, where on average only every eleventh shot actually hit a crystal. This resulted in a total of 293,195 diffraction images recorded. These could only be processed with massive parallel computing, to first generate a three-dimensional map of the entire diffracting signals of the enzyme from which an image of its structure was calculated. The final result revealed the enzyme's structure with a resolution of 2.1 Ångström (one Ångström is a tenth of a nanometre or a ten-millionth of a millimetre). "Interestingly, this discovery comes exactly at the centenary of the publication of the famous X-ray diffraction equation by William Bragg in 1912," Chapman pointed out.

The team included members from DESY, the Universities of Hamburg, Lübeck, Tübingen, Uppsala and Gothenburg, the Arizona State University, SLAC, Lawrence Livermore National Laboratory, the Max Planck institute for medical research in Heidelberg and the Max Planck advanced study group at CFEL. CFEL is a joint venture of DESY, the Max Planck society and the University of Hamburg. DESY is the leading German accelerator centre and one of the leading worldwide.
-end-
Reference: "Natively inhibited Trypanosoma brucei cathepsin B structure determined using an x-ray laser"; Lars Redecke, Karol Nass et al.; Science, 2012 (advance online publication); DOI: 10.1126/science.1229663

Helmholtz Association

Related Sleeping Sickness Articles from Brightsurf:

You can train your brain to reduce motion sickness
Visuospatial training exercises can train the brain to reduce motion sickness, providing a potential remedy for future passengers riding in autonomous vehicles.

'Morning sickness' is misleading and inaccurate, new study argues
The term 'morning sickness' is misleading and should instead be described as nausea and sickness in pregnancy, argue researchers led by the University of Warwick who have demonstrated that these symptoms can occur at any time of the day -- not just the morning.

Research team finds possible new approach for sleeping sickness drugs
Using ultra-bright X-ray flashes, a team of researchers has tracked down a potential target for new drugs against sleeping sickness: The scientists have decoded the detailed spatial structure of a vital enzyme of the pathogen, the parasite Trypanosoma brucei.

Insight into the neglected tropical disease sleeping sickness
Researchers have shed light on how the parasite which causes sleeping sickness multiples inside its host.

Severe morning sickness associated with higher risk of autism
Children whose mothers had hyperemesis gravidarum -- a severe form of a morning sickness -- during pregnancy were 53% more likely to be diagnosed with autism spectrum disorder, according to Kaiser Permanente research published in the American Journal of Perinatology.

Scientists identify a key gene in the transmission of deadly African sleeping sickness
An international team of life scientists has identified a key gene in the transmission of African sleeping sickness -- a severe disease transmitted by the bite of an infected, blood-sucking tsetse fly, which is common in Sub-Saharan Africa.

Marijuana for morning sickness? It's not great for baby's brain
With a growing number of states legalizing recreational or medical marijuana, more women are using the drug during pregnancy, in part due to its reported ability to relieve morning sickness.

New therapeutic approach to combat African sleeping sickness
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness.

Sleeping sickness parasite uses multiple metabolic pathways
Parasitic protozoa called trypanosomes synthesize sugars using an unexpected metabolic pathway called gluconeogenesis, according to a study published December 27 in the open-access journal PLOS Pathogens by David Horn of the University of Dundee in the UK, and colleagues.

Decoding sleeping sickness signals could aid quest for treatments
Scientists have discovered how the parasite that causes sleeping sickness initiates a physical change in order to spread the disease.

Read More: Sleeping Sickness News and Sleeping Sickness Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.